ARPA-H has committed $62.7 million to its ADVOCATE program, a bold initiative to develop AI agents for heart failure care. These systems are designed to autonomously adjust patient medications, diet, and exercise with limited human involvement, according to MedTech Dive. Atman Health has already been selected to develop one such agentic AI system specifically for cardiovascular care, focusing on heart failure, as reported by Dicardiology. The selection of Atman Health highlights the immediate operationalization of ARPA-H's vision for direct AI intervention in patient management.
This push for AI systems capable of autonomous patient care adjustments comes with a critical caveat: ARPA-H is simultaneously funding a separate AI designed to monitor these very agents for unsafe recommendations.
The healthcare system is thus moving towards a model where AI takes on more direct patient management, necessitating robust, AI-driven oversight mechanisms to ensure both safety and efficacy.
ARPA-H's Vision for Autonomous Heart Care
Launched on September 9, 2026, ARPA-H's ADVOCATE program aims to create the world's first FDA-authorized clinical AI system for cardiovascular care, as stated by BioBuzz. This ambitious goal involves developing systems capable of autonomously adjusting patient appointments, medications, diet, and exercise, according to Medical Daily. Initial teams, including Tempus AI, Updoc, and Atman Health, have been selected to build these patient-facing agentic systems. These AIs will support heart failure patients between visits and escalate critical issues to their care teams, as detailed by MedTech Dive. The program's focus on autonomous medication modification with limited human involvement, as reported by Medical Daily, signifies a profound shift: AI is moving beyond mere recommendations to direct, personalized therapeutic intervention, fundamentally reshaping the role of technology in chronic disease management.
